9- Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and comple-
ment activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane
tumor necrosis factor. Clin Immunol. 2009;131:308–16. - Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized,
double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–94. - Billmeier U, Dieterich W, Neurath MF, et al. Molecular mechanism of action of anti-
tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol.
2016;22:9300–13. - Dahlen R, Strid H, Lundgren A, et al. Infliximab inhibits activation and effector functions of
peripheral blood T cells in vitro from patients with clinically active ulcerative colitis. Scand
J Immunol. 2013;78:275–84. - Li L, Boussiotis VA. The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory
bowel disease and colon cancer. Clin Immunol. 2013;148:246–53. - Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses
by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology.
2005;128:376–92. - Van den Brande JM, Koehler TC, Zelinkova Z, et al. Prediction of antitumour necrosis factor
clinical efficacy by real-time visualisation of apoptosis in patients with Crohn’s disease. Gut.
2007;56:509–17. - Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a
comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21:251–8. - Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor
necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: com-
parison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–57. - Atreya R, Zimmer M, Bartsch B, et al. Antibodies against tumor necrosis factor (TNF) induce
T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal
CD14(+) macrophages. Gastroenterology. 2011;141:2026–38. - Yan L, Hu R, Tu S, et al. Establishment of a cell model for screening antibody drugs against
rheumatoid arthritis with ADCC and CDC. Int J Clin Exp Med. 2015;8:20065–71. - Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in
patients with ulcerative colitis. Gut. 2009;58:1612–9. - Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflam-
matory bowel disease: adding value to current practice. J Clin Pharmacol. 2015;55(Suppl
3):S39–50. - Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor
antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079–87;
quiz e85-6. - Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor
IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol
Ther. 2004;19:511–9. - Cornillie F, Shealy D, D’Haens G, et al. Infliximab induces potent anti-inflammatory and local
immunomodulatory activity but no systemic immune suppression in patients with Crohn’s
disease. Aliment Pharmacol Ther. 2001;15:463–73. - Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin
Pharmacokinet. 2007;46:645–60. - Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab
in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211–28. - Raghavan KS, Nemeth GA, Gray DB, et al. Solubility enhancement of a bisnaphthalimide
tumoricidal agent, DMP 840, through complexation. Pharm Dev Technol. 1996;1:231–8. - Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflam-
matory bowel disease patients. Ther Drug Monit. 2008;30:523–9. - Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biolog-
ics in IBD – the role of patient, product and prescriber factors. Aliment Pharmacol Ther.
2013;38:1188–97.
1 Mechanism of Action and Pharmacokinetics of Biologics